Jade Biosciences, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Jade Biosciences, Inc. (JBIO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$100.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-05-07
- Jade Biosciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$26.74M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$19.09M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$38.17M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-12-31 was -$30.11M.
- Jade Biosciences, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$100.14M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$26.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$45.83M derived: sum of 2 quarters · filed 2026-03-06 | -$100.14M 10-K · filed 2026-03-06 | |
| 2025-09-30 | -$19.09M 10-Q · filed 2025-11-14 | -$73.39M 10-Q · filed 2025-11-14 | ||
| 2025-03-31 | -$38.17M 10-Q · filed 2026-05-07 | -$68.28M derived: sum of 2 quarters · filed 2026-05-07 | -$85.15M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$30.11M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | -$46.98M 10-K · filed 2026-03-06 | ||
| 2024-09-30 | -$16.28M 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |